Impact of HIV-1 replication on immunological evolution during long-term dual-boosted protease inhibitor therapy.

about

Improved virological and immunological efficacy of resistance-guided switch in antiretroviral therapy: a Frankfurt HIV cohort analysis Vaccination against infectious diseases: what is promising?HIV-1 replication in central nervous system increases over time on only protease inhibitor therapy.

P2860

Q34518299-28D7E2C6-9FEC-442B-B9D6-4F8CC1B030D1 Q38234231-429FB5E7-93CE-4218-9D54-EAAE531BC5BC Q39548875-7086A3F2-AA08-4FDC-A226-B8C3C6DB791F

P2860

Impact of HIV-1 replication on immunological evolution during long-term dual-boosted protease inhibitor therapy.

Item

http://www.wikidata.org/entity/Q43760953

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Impact of HIV-1 replication on ...... ed protease inhibitor therapy.

@en

Impact of HIV-1 replication on ...... ed protease inhibitor therapy.

@nl

type

Item

label

Impact of HIV-1 replication on ...... ed protease inhibitor therapy.

@en

Impact of HIV-1 replication on ...... ed protease inhibitor therapy.

@nl

prefLabel

Impact of HIV-1 replication on ...... ed protease inhibitor therapy.

@en

Impact of HIV-1 replication on ...... ed protease inhibitor therapy.

@nl

P1476

Impact of HIV-1 replication on ...... ed protease inhibitor therapy.

@en

P2093

Annemarie Berger

http://www.w3.org/2001/XMLSchema#string

Christoph Stephan

http://www.w3.org/2001/XMLSchema#string

Eva Herrmann

http://www.w3.org/2001/XMLSchema#string

Gaby Knecht

http://www.w3.org/2001/XMLSchema#string

Hans-Reinhard Brodt

http://www.w3.org/2001/XMLSchema#string

Markus Bickel

http://www.w3.org/2001/XMLSchema#string

Nils von Hentig

http://www.w3.org/2001/XMLSchema#string

Pavel Khaykin

http://www.w3.org/2001/XMLSchema#string

Peter Gute

http://www.w3.org/2001/XMLSchema#string

Valentin Bartha

http://www.w3.org/2001/XMLSchema#string

P2860

Class-sparing regimens for initial treatment of HIV-1 infection.

Defining treatment failure in resource-rich settings.

The SnoB study: frequency of baseline raltegravir resistance mutations prevalence in different non-B subtypes.

High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial.

Raltegravir, etravirine, and ritonavir-boosted darunavir: a safe and successful rescue regimen for multidrug-resistant HIV-1 infection.

Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir.

Increased reporting of detectable plasma HIV-1 RNA levels at the critical threshold of 50 copies per milliliter with the Taqman assay in comparison to the Amplicor assay.

Plasma HIV-1 RNA detection below 50 copies/ml and risk of virologic rebound in patients receiving highly active antiretroviral therapy.

Traceability of 3 generations of nucleic acid amplification tests for quantitative HIV-1 RNA measurements to meet the WHO HIV-1 RNA International Standards.

Modifications and substitutions of the RNA extraction module in the ViroSeq HIV-1 genotyping system version 2: effects on sensitivity and complexity of the assay.

P2888

s00430-012-0276-8

P304

117-124

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00430-012-0276-8

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

202

http://www.w3.org/2001/XMLSchema#string

P50

Nils von Hentig

Martin Stürmer

P577

2012-09-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230864330

http://www.w3.org/2001/XMLSchema#string

P698

22983722

http://www.w3.org/2001/XMLSchema#string

P921

immunology

Impact of HIV-1 replication on immunological evolution during long-term dual-boosted protease inhibitor therapy.

about

P2860

P2860

Impact of HIV-1 replication on immunological evolution during long-term dual-boosted protease inhibitor therapy.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P921

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P921